Activated protein C protects against renal ischaemia/reperfusion injury, independent of its anticoagulant properties

Summary

Acute renal failure, a serious condition characterised by a drastic decline in renal function, often follows ischaemia/reperfusion (I/R) episodes. I/R is characterised by necrosis, inflammation and activation of coagulation, in concert causing renal tissue damage. In this context, activated protein C (APC) might be of importance in the pathogenesis of renal I/R. APC is a serine protease which has anticoagulant but also several anti-inflammatory and cytoprotective effects such as protection of endothelial barrier function. It was our objective to study the role of cytoprotective and anticoagulant functions of APC during renal I/R. C57BL/6j mice subjected to renal I/R were treated with intraperitoneally injected exogenous human APC, or two mutant forms of APC(200 µg/kg) which specifically lack anticoagulant or signalling properties. In a different experiment mice received specific monoclonal antibodies (20 mg/kg) that block the cytoprotective and/or anticoagulant properties of endogenous APC. Treatment with APC reduced tubular injury and enhanced renal function without altering the inflammatory response and did reduce renal fibrin deposition. Administration of APC mutant lacking anticoagulant properties reduced renal damage and enhanced renal function. Blocking the anticoagulant and cytoprotective functions of endogenous APC resulted in elevated tubular damage and reduced tubular cell proliferation, however, without influencing renal function or the inflammatory response. Furthermore, blocking both the anticoagulant and cytoprotective effects of APC resulted in dramatic renal interstitial haemorrhage, indicative of impaired vascular integrity. Blocking only the anticoagulant function of APC did not result in interstitial bleeding. In conclusion, the renoprotective effect of APC during I/R is independent of its anticoagulant properties.

Keywords

Acute Kidney Injury - haemostasis - ischaemia-reperfusion injury - kidney - protein C

• References

• 1 Gill N, Nally Jr. JV, Fatica RA. Renal failure secondary to acute tubular necrosis: epidemiology, diagnosis, and management. Chest 2005; 128: 2847-2863.
• 2 Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol 2008; 109: e102-107.
• 3 Devarajan P. Update on mechanisms of ischaemic acute kidney injury. J Am Soc Nephrol 2006; 17: 1503-1520.
• 4 Jang HR, Rabb H. The innate immune response in ischaemic acute kidney injury. Clin Immunol 2009; 130: 41-50.
• 5 Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J 1992; 06: 2561-2567.
• 6 Bae JS, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signalling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104: 2867-2872.
• 7 Madhusudhan T, Wang H, Straub BK. et al. Cytoprotective signalling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 2012; 119: 874-883.
• 8 Guo H, Zhao Z, Yang Q. et al. An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci 2013; 33: 6181-6190.
• 9 White B, Schmidt M, Murphy C. et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110: 130-134.
• 10 Brueckmann M, Hoffmann U, De Rossi L. et al. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 2004; 26: 106-113.
• 11 Grey ST, Tsuchida A, Hau H. et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153: 3664-3672.
• 12 Yuksel M, Okajima K, Uchiba M. et al. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88: 267-273.
• 13 Joyce DE, Gelbert L, Ciaccia A. et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
• 14 Sturn DH, Kaneider NC, Feistritzer C. et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102: 1499-1505.
• 15 Feistritzer C, Sturn DH, Kaneider NC. et al. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol 2003; 112: 375-381.
• 16 Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70.
• 17 Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-3184.
• 18 Finigan JH, Dudek SM, Singleton PA. et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-17293.
• 19 Keller SA, Moore CC, Evans SL. et al. Activated protein C alters inflammation and protects renal function in sepsis. J Surg Res 2011; 168: e103-109.
• 20 Gupta A, Berg DT, Gerlitz B. et al. Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol 2007; 18: 860-867.
• 21 Wang J, Yang L, Rezaie AR. et al. Activated protein C protects against myocardial ischaemic/reperfusion injury through AMP-activated protein kinase signalling. J Thromb Haemost 2011; 09: 1308-1317.
• 22 Park SW, Chen SW, Kim M. et al. Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischaemia and reperfusion injury in mice. Kidney Int 2009; 76: 739-750.
• 23 Kager LM, Wiersinga WJ, Roelofs JJ. et al. Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis). J Thromb Haemost 2013; 11: 282-292.
• 24 Xu J, Ji Y, Zhang X. et al. Endogenous activated protein C signalling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost 2009; 07: 851-856.
• 25 Lichtnekert J, Rupanagudi KV, Kulkarni OP. et al. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas (lpr) mice. J Immunol 2011; 187: 3413-3421.
• 26 Bos EM, Leuvenink HG, Snijder PM. et al. Hydrogen sulfide-induced hypometabolism prevents renal ischaemia/reperfusion injury. J Am Soc Nephrol 2009; 20: 1901-1905.
• 27 Roelofs JJ, Rouschop KM, Leemans JC. et al. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischaemia reperfusion injury. J Am Soc Nephrol 2006; 17: 131-140.
• 28 de Stoppelaar SF, van ’t Veer C, Claushuis TA. et al. Thrombocytopenia impairs host defense in gram-negative pneumonia derived sepsis. Blood 2014; 124: 3781-3790.
• 29 Schoots IG, Levi M, Roossink EH. et al. Local intravascular coagulation and fibrin deposition on intestinal ischaemia-reperfusion in rats. Surgery 2003; 133: 411-419.
• 30 Zhou XS, Qiao YF, Wu RP. et al. Study on related indexes of the coagulation and fibrinolytic system after renal ischaemia reperfusion injury in Wistar rats. Saudi Med J 2013; 34: 579-583.
• 31 Ushigome H, Sano H, Okamoto M. et al. The role of tissue factor in renal ischaemic reperfusion injury of the rat. J Surg Res 2002; 102: 102-109.
• 32 Ding JW, Tong XH, Yang J. et al. Activated Protein C Protects Myocardium Via Activation of Anti-apoptotic Pathways of Survival in Ischaemia-reperfused Rat Heart. J Korean Med Sci 2010; 25: 1609-1615.
• 33 Loubele ST, Spek CA, Leenders P. et al. Activated protein C protects against myocardial ischaemia/ reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol 2009; 29: 1087-1092.
• 34 Shibata M, Kumar SR, Amar A. et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischaemic stroke. Circulation 2001; 103: 1799-1805.
• 35 Cheng T, Liu D, Griffin JH. et al. Activated protein C blocks p53-mediated apoptosis in ischaemic human brain endothelium and is neuroprotective. Nat Med 2003; 09: 338-342.
• 36 Thiyagarajan M, Fernandez JA, Lane SM. et al. Activated protein C promotes neovascularisation and neurogenesis in postischaemic brain via protease-activated receptor 1. J Neurosci 2008; 28: 12788-12797.
• 37 Mosnier LO, Zlokovic BV, Griffin JH. Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb Haemost 2014; 112: 883-892.
• 38 Gupta A, Rhodes GJ, Berg DT. et al. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007; 293: F245-254.
• 39 Almac E, Johannes T, Mik E. et al. Activated protein C restores kidney function in endotoxin-induced acute renal failure in the rat. Critical Care. 2009 13. 01 P356.
• 40 Turunen AJ, Fernandez JA, Lindgren L. et al. Activated protein C reduces graft neutrophil activation in clinical renal transplantation. Am J Transplant 2005; 05: 2204-2212.
• 41 Wildhagen KC, Schrijver R, Beckers L. et al. Effects of exogenous recombinant APC in mouse models of ischaemia reperfusion injury and of atherosclerosis. PLoS One 2014; 09: e101446.
• 42 Hirose K, Okajima K, Taoka Y. et al. Activated protein C reduces the ischaemia/ reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 2000; 232: 272-280.
• 43 Kerschen EJ, Fernandez JA, Cooley BC. et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-2448.
• 44 Griffin JH, Zlokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol 2002; 39: 197-205.
• 45 Domotor E, Benzakour O, Griffin JH. et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003; 101: 4797-4801.
• 46 Cheng T, Petraglia AL, Li Z. et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-1285.
• 47 Dong W, Wang H, Shahzad K. et al. Activated Protein C Ameliorates Renal Ischaemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination. J Am Soc Nephrol 2015; 26: 2789-2799.